Candel Therapeutics, INC

Candel Therapeutics stockholders re-elected four Class II directors and ratified the appointment of KPMG LLP as the company's independent auditor.

Candel Therapeutics, Inc. has formalized the employment terms for its Chief Financial Officer, Charles Schoch, detailing salary, bonus, and severance provisions.

Candel Therapeutics announced Q1 2026 financial results, highlighting progress towards a Q4 2026 BLA submission for aglatimagene in prostate cancer and positive extended survival data in NSCLC.

Candel Therapeutics announced its Q4 and full-year 2025 financial results, highlighted by significant progress in its clinical pipeline, including plans for a pivotal Phase 3 trial for aglatimagene in NSCLC and a BLA submission for prostate cancer.

Candel Therapeutics announced the pricing of an underwritten public offering of 18.3 million common shares at $5.45 each, aiming to raise $100 million for clinical development and commercialization.

Candel Therapeutics announced a $100 million royalty funding agreement with RTW Investments, LP, contingent on FDA approval of CAN-2409 for prostate cancer.

Candel Therapeutics, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing progress in its clinical-stage biopharmaceutical development and financial performance.

Candel Therapeutics reports positive clinical trial data for CAN-2409 in prostate and NSCLC, secures new $130M debt facility, and extends cash runway into Q1 2027.

Candel Therapeutics, a clinical-stage biopharmaceutical company, reported net income for the first six months of 2025, driven by positive clinical trial results for its lead cancer immunotherapies and a significant warrant revaluation.

Candel Therapeutics reports a net income of $7.4 million for Q1 2025, driven by a change in the fair value of warrant liability, while continuing to advance its clinical-stage viral immunotherapies.

Candel Therapeutics, a clinical-stage biopharmaceutical company, released its third quarter 2024 financial results, highlighting ongoing clinical trials and financial challenges.

Candel Therapeutics reports a net loss of $30.5 million for the first half of 2024, while highlighting positive clinical data for its lead product candidates.

Candel Therapeutics reports positive Phase 3 prostate cancer data, secures $100M royalty deal, and plans pivotal trials for lung cancer, extending its financial runway into Q1 2028.

Candel Therapeutics' 10-K filing highlights positive clinical trial results for CAN-2409 in prostate, lung, and pancreatic cancers, along with progress in CAN-3110 for recurrent high-grade glioma.

Candel Therapeutics has filed an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive officers, and corporate governance.

Candel Therapeutics' 10-K filing highlights its clinical-stage biopharmaceutical focus on developing viral immunotherapies for cancer treatment, with key updates on its CAN-2409 and CAN-3110 programs.

Mark E. Sims, Chief Commercial Officer of Candel Therapeutics, Inc., was granted stock options for 285,000 shares.

Candel Therapeutics Chief Scientific Officer Francesca Barone sold 23,447 shares of common stock for approximately $10.06 per share, pursuant to a 10b5-1 trading plan.

Candel Therapeutics Chief Technology Officer, Seshu Tyagarajan, reported the sale of 7,000 common shares for approximately $70,140 under a pre-established 10b5-1 trading plan.

Candel Therapeutics Director Paul B. Manning acquired stock options valued at $10.30 per share, with 2,199 options granted on June 30, 2026, in lieu of cash payments.

Candel Therapeutics Director Joseph C. Papa acquired 1,331 shares of common stock through a stock option exercise, as detailed in a recent SEC Form 4 filing.

Nicoletta Loggia, a Director at Candel Therapeutics, Inc., acquired stock options on June 30, 2026, as part of a compensation arrangement.

Candel Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 23, 2026, to elect directors and ratify auditor appointment.

Candel Therapeutics, Inc. has filed a definitive proxy statement with the SEC.

Candel Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 17, 2025, to elect directors and ratify the appointment of KPMG LLP as its independent accounting firm.

Candel Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 26, 2024, to elect directors and ratify the appointment of KPMG LLP as its independent accounting firm.

RTW Investments, LP and Roderick Wong, M.D. have jointly filed a Schedule 13G, reporting beneficial ownership of 8.8% of Candel Therapeutics, Inc. common stock as of March 31, 2026.

BlackRock Inc. has reported a 4.2% beneficial ownership in Candel Therapeutics Inc. as of March 31, 2026, holding over 3 million shares.

BlackRock, Inc. has reported a 5.2% beneficial ownership stake in Candel Therapeutics Inc. common stock as of December 31, 2025.

Acorn Bioventures, L.P., along with its affiliates and manager Anders Hove, has disclosed a collective passive beneficial ownership of 5.2% of Candel Therapeutics, Inc.'s common stock.

Baker Bros. Advisors LP and its affiliates have filed an Amendment No. 1 to their Schedule 13G, disclosing a 4.99% beneficial ownership stake in Candel Therapeutics, Inc. as of March 31, 2025.

Northpond Ventures and its affiliated entities have filed an amended Schedule 13G, indicating they no longer beneficially own any shares of Candel Therapeutics, Inc. common stock as of December 31, 2024.